Preclinical evaluation of HIV-1 envelope immunogens in humanized mice
Preclinical evaluation of HIV-1 envelope immunogens in humanized mice
批准号:
10667351
负责人:
VIKRAM SRIVASTAVA
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-07-01 至 2023-06-30
关键词:
Animal ModelAntibodiesAntibody ResponseAntigensDevelopmentFormulationGenerationsGenesGenetically Engineered MouseGoalsHIVHIV vaccineHIV-1HumanImmunoglobulinsPeptidesPhase I Clinical TrialsPreclinical TestingTestingTransgenic Micehumanized mouseinnovationneutralizing antibodynovelpreclinical evaluationprogramsvaccine candidatevaccine strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Genetically Engineered Mice for Pre-clinical Evaluation of HIV Vaccine Candidates: The development of novel HIV candidate vaccines generally requires preclinical testing in animal models before proceeding to Phase I clinical trials. Multiple efforts have focused on developing and evaluating innovative platforms and formulations of HIV envelope (Env) immunogens for the induction and generation of a durable and broadly neutralizing antibody (bNAb) response. The goal of this program is to utilize genetically engineered mouse models, such as human immunoglobulin KI or other transgenic mice expressing relevant human genes, to accelerate testing and development of HIV vaccine candidates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金